Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01295931 · ClinicalTrials.gov registry record · Phase 1
Nuclear and Near-Infrared (NIR) Imaging in Melanoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01295931: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01295931 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01295931, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Objectives: 1. To determine the feasibility of using microdose amounts of near-infrared (NIR) fluorescent contrast agent to image tumor-draining and contralateral lymphatics in melanoma patients prior to standard-of-care sentinel lymph node biopsy OR completion lymph node dissection (axillary or inguinofemoral) 2. To determine the feasibility of using nonradioactive optical imaging techniques with indocyanine green (ICG) as a fluorescent contrast agent to characterize lymphatic architecture and function by correlating the observed lymphatic structure and function with tumor and nodal status as determined from standard-of-care immunohistochemical evaluation.
Interventions
- DRUG Indocyanine Green (IC-Green)
- PROCEDURE Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01295931
The ClinicalTrials.gov registry entry for NCT01295931 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Indocyanine Green (IC-Green) is the first listed.
NCT01295931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01295931 about?
NCT01295931 is a clinical study titled "Nuclear and Near-Infrared (NIR) Imaging in Melanoma". Objectives: 1. To determine the feasibility of using microdose amounts of near-infrared (NIR) fluorescent contrast agent to image tumor-draining and contralateral lymphatics in melanoma patients prior to standard-of-care sentinel lymph node biopsy OR completion lymph node dissection (axillary or in...
What is the current status of trial NCT01295931?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-02. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01295931?
The interventions under investigation include: Indocyanine Green (IC-Green) (DRUG), Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT01295931?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.